@ dancinginthedark @ ratna1
quote:
"Acasti Pharma Inc. (ACST) shares dropped 54% to $1 after the company reported topline results for the primary endpoint, triglyceride reduction at 12 and 26 weeks, from its Phase 3 Trilogy 1 trial for its lead product candidate, CaPre, came in close to the placebo arm.
The biopharmaceutical company said the study showed a 30.5% median reduction in triglyceride levels among all patients receiving CaPre, compared with a 27.5% median reduction in triglyceride levels among patients receiving placebo at 12 weeks. "
________________________________________________________________________
quote:
"Cannot vouch for my memory being 100% correct but I do seem to recall that STREGTH also used corn oil as placebo. Maybe you are not in the dark but on to something!"
________________________________________________________________________
HOW DO I INVEST IN CORN OIL & CORN STARCH FUTURES????
Looks like the placebo works fairly well!
Cheers!
Flubber